Affinity DataIC50: 0.490nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 0.490nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 0.570nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 0.570nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 0.640nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 0.640nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 0.700nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 0.790nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 0.790nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.10nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.60nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.80nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.80nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.90nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.90nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.90nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 2.10nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 2.20nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 2.20nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
TargetCellular tumor antigen p53 [1-83]/E3 ubiquitin-protein ligase Mdm2 [1-188](Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 2.30nMAssay Description:The ELISA assay was performed in streptavidin coated plates which were preincubated with 200 μl per well of 1 μg ml−1 biotinylated IP...More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:The activity of DPP1 was determined by measuring the enzymatic release of aminomethyl coumarin (AMC) from the peptide substrate (H-Gly-Arg-AMC), whic...More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:The activity of DPP1 was determined by measuring the enzymatic release of amino methyl coumarin (AMC) from the peptide substrate (H-Gly-Arg-AMC), whi...More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:The activity of DPP1 was determined by measuring the enzymatic release of aminomethyl coumarin (AMC) from the peptide substrate (H-Gly-Arg-AMC), whic...More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:The activity of DPP1 was determined by measuring the enzymatic release of aminomethyl coumarin (AMC) from the peptide substrate (H-Gly-Arg-AMC), whic...More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:The activity of DPP1 was determined by measuring the enzymatic release of aminomethyl coumarin (AMC) from the peptide substrate (H-Gly-Arg-AMC), whic...More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:Examples 1-35: The activity of DPP1 was determined by measuring the enzymatic release of aminomethyl coumarin (AMC) from the peptide substrate (H-Gly...More data for this Ligand-Target Pair